New Cytotoxic Agents in Secondary and Treatment-related AML: Practical Strategies for Optimizing Outcomes
Release Date: January 9, 2019
Expiration Date: January 9, 2020
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Many prognostic factors are related to the sensitivity of acute myeloid leukemia to currently available therapies. In this activity, Dr. Harry Erba focuses on antecedent hematologic disorders leading to secondary AML and treatment-related AML. He also explains the standard of care for incorporating therapeutic agents into the treatment of patients with secondary AML and treatment-related AML in your clinical practice.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Identify the prevalence, characteristics, and clinical impact of secondary AML (sAML) and therapy related AML (tAML)
- Outline current treatment options for sAML and tAML
- Describe the standard of care for incorporating therapeutic strategies into the treatment of patients with sAML and tAML
New Cytotoxic Agents in Secondary and Treatment-related AML: Practical Strategies for Optimizing Outcomes - Harry P. Erba, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through January 09, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Durham, North Carolina
Dr. Harry Erba received his medical degree and doctorate in biophysics from Stanford University. He completed an internship and residency in internal medicine, as a well as a fellowship in hematology/oncology at the Brigham and Women's Hospital, Harvard Medical School. He was previously Professor of Internal Medicine at the University of Alabama at Birmingham (UAB), served as Director of the Hematologic Malignancy Program, and was Associate Director for Clinical Research in the UAB Comprehensive Cancer Center. Dr. Erba held the Alfred F. LoBuglio Endowed Chair for Translational Cancer Research from 2013 through 2018. He is currently Professor of Internal Medicine at Duke University, and is a faculty member of the Division of Hematologic Malignancy and Cellular Therapy. In addition, Dr. Erba serves as the Director of the Leukemia Program, as well as Director of Phase I Unit for Hematologic Malignancies. He is a member of the Duke Cancer Institute.
As an active member in the SWOG (formerly, Southwest Oncology Group) Leukemia Committee for over a decade, Dr. Erba worked closely with the leadership of the SWOG Leukemia, Lymphoma, Myeloma and Bone Marrow Transplant Committees. He was appointed Chairman of the SWOG Leukemia Committee, and now serves on the NCI Leukemia Steering Committee. He also served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and myeloid growth factors.
Dr. Erba has focused on the assessment of novel therapies in AML, MDS, CML, and other myeloproliferative neoplasms. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials, and played major roles in the development of several new drugs.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-003-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Harry Erba has received consultant fees from Agios; Celgene Corporation; Daiichi Sankyo, Inc.; GlycoMimetics, Inc.; ImmunoGen, Inc.; Incyte Corporation; Jazz Pharmaceuticals plc; MacroGenics, Inc.; Novartis AG; Pfizer Inc.; Ono Pharmaceutical Co., Ltd.; and Seattle Genetics, Inc., as well as honoraria related to speakers’ bureau activities from Agios; Celgene; Incyte; Jazz; and Novartis. He has received grant support related to research activities from Agios; Amgen Inc.; Astellas Pharma US, Inc.; Daiichi Sankyo; ImmunoGen; Janssen Pharmaceuticals, Inc.; Juno Therapeutics; Pfizer; Seattle Genetics; and Takeda Oncology. He has also disclosed additional financial relationships with Celgene (Chair, Scientific Steering Committee for MDS/AML Registry Study) and GlycoMimetics (Chair, DSMB).
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.